Home Medicine Effects of chromium picolinate on the parameters of oxidative and chromosomal DNA damage in rabbits
Article Publicly Available

Effects of chromium picolinate on the parameters of oxidative and chromosomal DNA damage in rabbits

  • Meryem Şentürk ORCID logo EMAIL logo , Fatma Uyanık and Zuhal Hamurcu
Published/Copyright: September 9, 2017
Download Article (PDF)
Turkish Journal of Biochemistry
From the journal Turkish Journal of Biochemistry Volume 43 Issue 2

Abstract

Objectives

This study investigated the effects of chromium chloride (CrCl3·6H2O), chromium picolinate (CrPic) and picolinic acid on malondialdehyde (MDA), 8-hidroksi-2′-deoksiguanosine (8-OHdG) and genome damage in rabbits.

Material and methods

Forty, New Zealand rabbits were equally assigned to four groups which received either distilled water or 20 mg/day Cr (CrC13·6H20), 200 μg/day CrPic and 1400 μg/day picolinic acid for 50 days. On the 25th and 50th days, MDA and 8-OHdG levels and the apoptotic-necrotic cells, micronucleus (MN), micronuclear buds (NBUD) and nucleoplasmic bridges (NPB) frequencies and on the 50th day, serum Cr and liver MDA levels were determined.

Results

CrPic increased live weight and feed consumption. On the 25th day of treatment, decreases were detected in MDA levels and MN, NPK and NBUD frequencies in CrPic and picolinic acid groups, and in 8-OHdG levels in CrCl3·6H2O and CrPic groups. Slight or significant differences were determined in all investigated parameters between the measurements of on days 25 and 50.

Conclusion

Improvements in of MDA and 8-OHdG levels and genome damage indicators due to CrPic and picolinic acid on the 25th day of the treatment may show that short term of CrPic supplementation reduces oxidative and chromosomal DNA damage in rabbits.

Özet

Amaç

Bu çalışma, tavşanlarda krom klorür (CrCl3·6H2O), krom pikolinat (CrPic) ve pikolinik asidin malondialdehit (MDA), 8-hidroksi-2′-deoksiguanozin (8-OHdG) ve genom hasarı üzerine etkilerinin belirlenmesi amacıyla gerçekleştirildi.

Gereç ve Yöntem

Çalışmada 40 Yeni Zelanda tavşanı, eşit sayıda olacak şekilde 4 gruba ayrılarak distile su veya CrCl3·6H2O formunda 20 mg/gün Cr, 200 μg/gün CrPic ve 1400 μg/gün pikolinik asit 50 gün verildi. Denemenin 25. ve 50. günlerinde MDA ve 8-OHdG düzeyleri ve apoptotik -nekrotik hücre sayıları, mikronükleus (MN), nükleoplazmik köprü (NPK) ve nükleer bud (NBUD) sıklığı ile denemenin 50. gününde serum Cr ve karaciğer MDA düzeyleri belirlendi.

Bulgular

Chromium picolinate (CrPic) yem tüketimi ve canlı ağırlığı arttırdı. Çalışmanın 25. gününde, CrPic ve pikolinik asit verilen gruplarda MDA düzeyleri ile MN, NPK ve NBUD sıklığı, CrCl3·6H2O ve CrPic verilen gruplarda da 8-OHdG düzeyleri azaldı. İncelenen tüm parametreler yönünden 25. ve 50. günlerde yapılan ölçümler arasında önemsiz yada önemli farklılıklar saptandı.

Sonuç

Çalışmanın 25. gününde CrPic ve pikolinik asit; MDA, 8-OHdG ve genom hasarı göstergelerinde iyileşmeye neden olduğundan tavşanlara kısa süreli CrPic verilmesinin oksidatif ve kromozomal DNA hasarının önlenmesinde etkili olabileceği kanaatine varıldı.

Keywords: Apoptosis; Chromium picolinate; DNA damage; Micronucleus; Oxidative stress
Anahtar Kelimeler: Apoptozis; DNA hasarı; Krom pikolinat; Mikronükleus; Oksidatif stress

Introduction

Trivalent chromium (Cr+3) is an essential trace element that is required for the regulation of carbohydrate, lipid, protein and nucleic acid metabolisms [1], [2], [3]. Several studies have claimed that chromium deficiency can lead to symptoms similar to type 2 diabetes, cardiovascular disease and glucose intolerance; growth retardation, lack of glucose and lipid homeostasis [2], [3] and these symptoms can be reversed with chromium supplementation [1], [2], [3].

Chromium compounds are found in organic and inorganic forms [4]. The absorption of inorganic chromium is poor due to the difficulty of passing through the membranes [5]. Solely 0.04%–2% of Cr+3 taken in the body can be absorbed and this absorption is affected by oxalate, iron and carbohydrates present in the nutrients [6], [7]. Therefore, several compounds were chelated with organic substances such as picolinic acid, nicotinic acid, propionic acid and methionine to increase the absorption of chromium [8] thus organic Cr compounds are more readily absorbed compare to the inorganic compounds [9].

Previous studies have shown the beneficial effects of chromium compounds on body development in human [10], [11] and performance [12], [13], [14], [15], [16], [17], carcass traits [18], [19] and immunity [14], [20] in several animal species. Some previous studies suggested that CrCl3 inhibits lipid peroxidation and ROT formation [21], reduced elevated malondialdehyde (MDA) level in quail exposed to heat stress [13], [22].

Chromium picolinate (CrPic) is commonly used as a dietary supplement particularly in human. In the form of CrPic, 5 and 10 mg/kg Cr reduced oxidative stress and inflammation in obese rats [23] and 100 and 250 mg/kg CrPic did not cause DNA damage in diabetic obese mice [24]. However, some studies investigating the effects CrPic on people in details showed no beneficial effects on weight loss, fat loss and tissue size [25], [26] some other studies claimed even adverse effects such as cytotoxicity and genotoxic of this organic chromium compound [27], [28], [29]. Moreover, the safety of CrPic has been questioned recently. It has been claimed that CrPic causes chromosomal damage due to the picolinate content [30]. In physiological conditions, the CrPic is reduced to Cr+2 compounds by biological reductants such as ascorbic acid and thiol, which are air sensitive. These reductants create hydroxyl radicals that cause deoxyribonucleic acid (DNA) damage [31], [32]. Studies suggesting the cytotoxic and genotoxic effects of CrPic were generally carried out in vitro [24], [31], [33]. However, limited studies investigated the effects of CrPic on similar variables at in vivo conditions [29], [34].

In the previous studies investigating possible cytotoxic and genotoxic effects of CrPic, conflicting results have been reported [27], [29], [35], [36]. Therefore, the presented study was performed in rabbits to investigate the effects of trivalent chromium as an inorganic form, CrCl3, and a commonly used organic form especially in human, CrPic, along with the picolinic acid (C6H5NO2), which was accused to have clastogenic effects, on serum and liver levels of (MDA), which is an indicator of oxidative stress, and plasma 8-OHdG, an indicator of oxidative DNA damage. In addition, it was investigated that whether these inorganic and organic chromium compounds cause genomic damage.

Materials and methods

Animals, management and experimental design

In the study, 40, 16 weeks old New Zealand rabbits obtained from the Hakan Çetinsaya Experimental and Clinical Research Center, Faculty of Medicine (DEKAM), University of Erciyes were used. Animals were maintained in polycarbonate cagessized 48×61×46 cm (two rabbits in each) at this center that provides the highest possible health status and appropriate high standard conditions (21°C±2°C room temperature, 50%±5% humidity, environmental ventilation systems providing air flow rotation of 12 per hour and 12 h light-12 h dark lightening schedule) for the animal welfare throughout the study.

A commercially available pellet diet for rabbits containing 2500 kcal/kg metabolizable energy (ME), 17% crude protein and 1648 ppm Cr by analysis that met the daily nutritional requirement of the rabbits and routinely used for the feeding of rabbit in DEKAM was provided throughout the experiment. Water and feed were supplied ad libitum during the study. In the beginning of the study, all animals were weighed to provide equal mean live weight of the groups, and they assigned into four groups containing 10 animals (five male, five female) in each. Rabbits in groups I (control), II, III and IV received either 2 mL distilled water or 20 mg/day Cr as CrC13·6H20, 200 μg/day CrPic and 1400 μg/day picolinic acid, which is the picolinic acid level in CrPic, respectively by the gavage method for 50 days. The above mentioned Cr levels were used in the present study because 20 mg/kg of CrC13 had been found to be effective in the studies [17], [18], the daily level of CrPic used in humans had been assumed to be 200 μg, 1400 μg picolinic acid corresponds to the level of picolinic acid contained in CrPic. This study was approved by the Erciyes University Experimental Animal Ethics Committee with approval no. 10/67 dated 11.08.2010.

Data and sample collection

Live weights after 12 h fasting and feed consumption of the animals were recorded at weekly intervals. Blood samples (5–6 mL) were collected from V. auricularis caudalis of the animals on 25th and 50th days of the experiment into tubes with heparin for CBMN cyt and 8-OHdG analyses and without anticoagulants for MDA and Cr analyses. Plasmas were separated immediately and sera were separated by centrifugation at 1300×g for 10 min following 1 h incubation at room temperature. Samples were aliquoted into cryovials, and plasma samples for 8-OHdG and serum samples for MDA were kept at −80°C whereas sera for Cr analyses were stored at −20°C until analyses.

At the end of the experiment, rabbits were euthanized with 45–50 mg/kg of ketamine/xylazine mixture. Collected liver samples into sterile plastic bags were transferred to the laboratory under cold chain, and immediately processed for MDA analysis. Liver samples weighing 25 mg were put into 1.5 mL of sterile cryovials. The RIPA buffer (Cayman, 10010263) containing 250 μL protease inhibitor was added to each vial, and sonicated at 40 V for 15 s under ice then centrifuged at 4°C at 1600×g for 10 min. Separated tissue supernatants were kept at −80°C until the determination of MDA levels.

Food samples were collected from five different parts of the feed bulk, and these samples were combined and blended then chemical analysis of the food was performed according to A.O.A.C. [37]. ME was calculated according to Carpenter ve Clegg [38].

Measurement of the MDA and 8-OHdG levels

Serum and tissue MDA (TBARS ELISA Kit, Cayman, USA, Cat. no 10009055) and plasma 8-OHdG (Nortwest Life Science Specialistand LLC, Washington, Code: NWK 8-OHdG 02) levels were determined by enzyme linked immunosorbent assay (ELISA) according to the instruction of manufacturers of commercially available kits using μQuant (Bio-Tek) ELISA reader.

Measurement of chromium in food and sera

Feed and serum chromium levels were determined at Erciyes University Technology Research and Application Center. The food sample (250 mg) in Teflon cell was digested with 5 mL of 65% HNO3 in microwave for 20 min then analyzed with ICP/MS (Agilent 7500a series). Standard solutions containing 0, 1, 5, 10, 20, 30, 40, 50 ppb chromium, and for correction of the bias in calibration curve, internal standards containing Be, Sc, Ra and Bi were used for determination of chromium in food and serum samples.

T-Lymphocyte cultures

Two sets of T-lymphocyte culture were prepared from each rabbit immediately. An amount of 0.4 mL whole blood sample taken from heparin containing tubes were inoculated into tubes containing 4 mL peripheral blood karyotyping medium (complete culture medium w/o phytohemagglutinin; Biological Industries, B-01-198-1B) then incubated at 37°C for 72 h for cytokinesis-block micronucleus cytome assay (CBMN cyt).

Cytochalasin-B (cyt-B) (Sigma-Aldrich Co., St. Louis, MO, USA Cat. no:6762) measuring 75 μL was added to the cultures providing a 3 μg/mL final concentration at 44 h of incubation for determination of binucleated cells. Incubation was terminated at 72 h, the cultures were treated for 4 min with hypotonic 0.1 M KCl solution (Merck, 340TA611835), and fixed in two cycling of cold methanol:glacial acetic acid (3:1) (Merck, 247K18855556.). The fixed cells were spread onto glass slides and stained with 6% Giemsa for 8 min. Four slides from two parallel cultures of each rabbit were prepared. All of the slides were coded and blind red.

Examination of the slides

Slides were examined under an optical microscope (Zeiss Primo Star) at ×40 magnification. The number of micronucleus (MN), micronuclear buds (NBUD) and NPB in 1000 binucleated cells were recorded to determine DNA damage. To determine the cell proliferation rate, 1000 mononuclear cells were counted, and binucleated and multinucleated cells were scored. Nuclear Division Index (NDI) was calculated using the following formula: NDI=(M1+2M2+3M3+4M4)/N. Membrane blebs and condensed and pyknotic nuclei in cells were considered as indicators of apoptosis. Swollen cells, lysis in cell membranes and leakage of cell content were accepted as necrosis. Apoptotic and necrotic cells were scored in 1000 mononuclear cells for cell death. The frequencies of MN, NBUD, NPB and NDI were calculated as the percentage for each rabbit.

Analysis of data

Statistical analysis of the data was performed with SPSS 15.0 software package. Number of total rabbits (40) and rabbits (n=10) in each group were determined with G-Power software (84%). The normality testing of the data were determined with Shapiro-Wilk test. The difference between the groups was detected with one-way analysis of variance (ANOVA). When F values were significant, Duncan Multiple Comparison Test was performed. The differences between groups and within groups were determined with repeated measures ANOVA. All data were expressed as means±standard deviation of means (SD) unless otherwise stated.

Results

At the end of the experiment, compare to control group, live weight increased significantly in CrCl3·6H2O (p=0.003) and picolinic acid given animals whereas the increase in CrPic group could not reach significance. However, overall live weight changes showed a significant increase only in animals given CrPic (p=0.026). The food consumption was also higher in CrPic group (Table 1).

Table 1:

Live weight and food consumption of rabbits receiving chromium (III) chloride, chromium picolinate and picolinic acid.

VariablesControl (n=10) X̅ ± SDCrCl3·6H2O (20 mg/day) (n=10)

X̅ ± SD		CrPic (200 μg/day) (n=10)

X̅ ± SD		Picolinic acid (1400 μg/day) (n=10)

X̅ ± SD		p-Value
Live weight (kg)
 At the beginning2.61±0.35a2.80±0.40a2.50±0.17a2.77±0.21a0.061
 At the end2.91±0.23b,d3.23±0.28b,c3.04±0.14b,c,d3.17±0.18b,c0.003
p-Value0.0370.0180.0000.001
Live weight changes (kg)0.30±0.21d0.43±0.30c,d0.54±0.38c0.40±0.28c,d0.026
Total food consumption (kg)4.774.875.174.52

  1. a,bThe values with different superscripts in the same column differ significantly. c,dThe values with different superscripts in the same row differ significantly. X̅ ± SD, means±standard deviation of means.

MDA levels on 25th day of treatment of the study decreased (p=0.007) in CrPic and picolinic acid-treated groups compare to the control group, and no significant difference was determined between the CrCl3·6H2O and the control groups. At the end of the study, there was no significant difference between control and treatment groups. Considering the differences between sampling times, MDA levels in control and CrCl3·6H2O given groups were significantly lower (respectively p=0.001, p=0.000) on 50th day of treatment than 25 whereas no difference was determined in animals treated with CrPic and picolinic acid. Chromium and picolinic acid treatments had no effects on tissue MDA and serum Cr levels (Table 2).

Table 2:

The malondialdehyde, 8-hydroxy-2′-deoxyguanosine and chromium levels in rabbits receiving chromium (III) chloride, chromium picolinate and picolinic acid.

ParametersControl

X̅ ± SD		CrCl3.6H2O (20 mg/day)

X̅ ± SD		CrPic (200 μg/day)

X̅ ± SD		Picolinic acid (1400 μg/day)

X̅ ± SD		p-Value
MDA (μmol/L)n=10n=10n=10n=10
Day 256.22±3.04a,c5.81±1.63a,c4.31±1.33d4.16±1.10d0.000
Day 502.13±0.58b2.41±0.87b3.11±1.793.18±1.440.126
p-Value0.0010.0000.0630.065
8-OHdG (ng/mL)n=10n=10n=10n=10
Day 254.82±1.20a,c3.70±1.32a,d3.73±0.80d5.05±0.69a,c0.000
Day 503.33±0.95b2.85±0.86b3.03±0.662.52±0.64b0.069
p-Value0.0100.0280.0470.000
Liver MDA (μmol/L) (Day 50)n=6n=6n=6n=6
12.36±3.6312.98±3.1111.55±2.1410.76±2.000.555
Serum Cr (ppm) (Day 50)n=6n=6n=6n=6
0.0495±0.0160.0762±0.0130.0568±0.0210.0507±0.0120.061

  1. a,bThe values with different superscripts in the same column differ significantly. c,dThe values with different superscripts in the same row differ significantly. X̅ ± SD, means±standard deviation of means.

Plasma 8-OHdG levels decreased in CrCl3·6H2O and CrPic (p=0.000) given groups but no difference was observed between control and picolinic acid groups on the 25th day of treatment. At the end of the study, compare to control, slight but not significant decreases were determined in 8-OHdG levels in all treatment groups. No difference was seen between the 8-OHdG levels determined at first and second sampling times in CrPic group whereas significant decreases occurred in control, picolinic acid (p=0.000) and CrCl3·6H2O (p=0.028) treated animals on the 50th day of treatment compare to 25th day of treatment (Table 2).

The frequencies of MN in CrPic and MN, NPK, NBUD in picolinic acid treated rabbits decreased (p=0.007), CrCl3·6H2O had no effect on these parameters on the 25th day of treatment. However, none of the treatments affected the MN, NPK, NBUD frequencies on the 50th day of treatment (respectively p=0.084, p=0.145, p=0.271). The frequencies of MN (p=0.021) and NBUD (p=0.000) in control; MN (p=0.035), NPK (p=0.000) and NBUD (p=0.002) in CrCl3·6H2O; NPK (p=0.014) in CrPic given animals were lower on the 50th day of treatment than the percentages determined on the 25th day of treatment. No time effect of picolinic acid on MN, NPK and NBUD frequencies was observed (Table 3).

Table 3:

The frequencies of micronuclei, micronuclear buds and nucleoplasmic bridges in cultured peripheral lymphocytes of rabbits receiving chromium (III) chloride, chromium picolinate and picolinic acid.

ParametersControl

X̅ ± SD		CrCl3·6H2O (20 mg/day)

X̅ ± SD		CrPic (200 μg/day)

X̅ ± SD		Picolinic acid (1400 μg/day)

X̅ ± SD		p-Value
MN (%)n=6n=6n=6n=6
Day 251.78±0.82a,c1.20±0.49a,c,d0.83±0.37d0.92±0.41d0.007
Day 500.77±0.37b0.62±0.31b0.75±0.411.08±0.280.084
p-Value0.0210.0350.7200.427
NPK (%)n=6n=6n=6n=6
Day 250.90±0.93c0.98±0.40a,c0.63±0.38a,c,d0.10±0.09d0.000
Day 500.13±0.190.08±0.13b0.17±0.05b0.28±0.170.145
p-Value0.0750.0000.0140.063
NBUD (%)n=6n=6n=6n=6
Day 258.40±2.57a,c7.12±2.91a,c6.85±1.99c4.17±0.47d0.001
Day 502.42±0.69b3.40±0.68b5.40±6.293.83±1.340.271
p-Value0.0000.0020.5580.577

  1. a,bThe values with different superscripts in the same column differ significantly. c,dThe values with different superscripts in the same row differ significantly. X̅ ± SD, means±standard deviation of means.

No difference was detected between groups concerning the apoptotic cell percentage on both 25th and 50th days of treatment. Necrotic cell counts in all of the treatment groups significantly decreased (p=0.000) on the 25th day of treatment whereas the necrotic cell percentage was significantly lower (p=0.000), solely in picolinic acid-treated animals than controls on the 50th day of treatment. Apoptotic (p=0.006) and necrotic (p=0.000) cell counts in control, necrotic cell counts in CrCl3·6H2O (p=0.012) and in picolinic acid (p=0.011) treated groups were lower on the 50th day of treatment than the levels determined on the 25th day of treatment. No time effect was detected in CrPic group (Table 4).

Table 4:

The cell death percentages in cultured peripheral lymphocytes of rabbits receiving chromium (III) chloride, chromium picolinate and picolinic acid.

ParametersControl

X̅ ± SD		CrCl3·6H2O (20 mg/day)

X̅ ± SD		CrPic (200 μg/day)

X̅ ± SD		Picolinic acid (1400 μg/day)

X̅ ± SD		p-Value
Apoptotic cells (%)n=6n=6n=6n=6
Day 256.75±1.98a4.77±3.183.82±0.928.35±5.410.054
Day 503.62±0.92b3.30±0.995.67±4.914.07±1.870.368
p-Value0.0060.3060.3860.097
Necrotic cells (%)n=6n=6n=6n=6
Day 2530.28±9.93a,c12.33±4.99a,d7.12±3.82d6.53±2.19a,d0.000
Day 506.12±1.62b,c5.92±1.09b,c6.23±0.94c3.40±1.17b,d0.000
p-Value0.0000.0120.5940.011

  1. a,bThe values with different superscripts in the same column differ significantly. c,dThe values with different superscripts in the same row differ significantly. X̅ ± SD, means±standard deviation of means.

Discussion

Previous studies have showed that dietary trivalent chromium is involved in carbohydrate, lipid, protein and nucleic acid metabolisms [2], [17], and positively affects performance [14], [16] and carcass traits in several animal species [18], [19]. No effects of chromium on the live weight of the broilers [12], and laying quail [17], [19] supplemented with 20 mg/kg Cr in the form of CrCl3·6H2O have been reported. However, some other studies indicated increases in live weight of broilers with CrPic [13] and CrCl3·6H2O [15] and in turkey poults with chromium nicotinate supplementation [39]. In the presented study, a 50 day treatment of rabbits with inorganic and organic chromium compounds and picolinic acid increased live weight of the animals. The increased live weight reached significance in solely CrPic treated rabbits (p=0.023) those food consumption were also higher than control and the other treated animals. The increases in live weight may either resulted from increased food intake or may be resulted from better absorption and availability of this organic chromium complex [7], [40].

In recent years, CrPic is widely used as a supplement by people in many countries in various forms such as chewing gum, sports drinks, nutritional bars and drug in addition to the chromium provided by food [41]. However, despite the studies indicating the beneficial impact of CrPic [14], [16], [18], [19], the use of the CrPic safely has been questioned [31], [34], [41] recently due to the presence of several studies claiming the deleterious effects of this synthetic chromium compound on cell structure and DNA [27], [29], [30].

It has been demonstrated that air sensitive biological reductants such as ascorbic acid and thiol, which create hydroxyl radicals (HO˙) leading the damage of DNA, reduce the trivalent chromium in CrPic to Cr+2 [32]. Formation of HO˙ and increases in cell damage with high level of CrPic have been reported by Stearns et al. [30] and Bagchi et al. [31]. In addition, the physiological concentrations (50–260 ppb) of the CrPic were also accused for the reactive oxygen species (ROS) formation [34] where as it has been suggested that CrCl3 avoids the ROS formation by suppressing the lipid peroxidation [21].

The MDA, one of the most frequently synthesized lipid peroxidation products [42] can reach the detectable level in blood and urine under oxidative stress conditions [43]. The increased MDA level due to oxidative stress has been shown to be decreased by chromium treatment supplementation [3], [17]. In patients with type 2 diabetes, the increased thiobarbituric acid-reactive substances (TBARS) level due to high plasma glucose and autooxidation of small molecules was reduced by 18.2% with 400 μg/day chromium pidolate by Anderson et al. [3]. In a hamster study performed by Vinson et al. [22], the combined chromium and grape seed extract reduced TBARS level by 77%.

The reduction in MDA content of the CrPic and picolinic acid groups (p=0.000) on 25th day of treatment supports the decline in the elevated serum MDA levels exposed to heat stress and chromium treatment [17]. In a rat study of Preuss et al. [44], supplementation of diet with 5 mg/kg of chromium acetate and chromium nicotinate reduced TBARS where as CrPic less effective. CrCl3 had no effect on renal and hepatic TBARS. Contrary to the results of Preuss et al. [44], in the presented study, CrPic and picolinic acid significantly decreased serum MDA (p=0.000) levels. CrPic and picolinic acid treatments also resulted in a slight but not significant decrease in liver MDA level. However, no effect of CrCl3·6H2O on serum and liver MDA levels confirms the findings of Preuss et al. [44] who did not determine any effect of CrCl3 on renal and hepatic TBARS. Lack of the effect of chromium on liver MDA level may be due to short residential time of this element in the cells thus lower accumulation in the liver, and may also due to the separation of this chelated compound into its components by the modification occurred in hepatocyte microsomes [21]. Furthermore, absence of the effects of CrPic and CrCl3·6H2O on serum chromium level may result from the maintenance of the chromium in blood stream for short-term because of rapid excretion of chromium from organism [45].

In the organism, 8-OHdG is generated by the insertion of a OH group to C8 atom of guanine molecule through ROS [46]. In a study conducted in the calf’s thymus, no effect of the trace metals such as CHCl3 on the 8-OHdG stimulation was reported [47]. Chang et al. [48] have determined a fall in liver 8-OHdG level in parallel with the decrease in oxygen free radical levels in New Zealand rabbits. Similarly, in the presented study, on 25th day of treatment, decrease in serum MDA levels in animals treated with CrPic (p=0.000) and CrCl3·6H2O (slight but not significant) were in harmony with the decrease in plasma levels of 8-OHdG (p=0.000). As 8-OHdG is an important indicator of oxidative DNA damage induced by ROS [49], the declines both in MDA and 8-OHdG indicates no deleterious effect of CrPic on DNA, instead this organic chromium compound would be helpful in preventing ROS dependent DNA damage.

Morphological changes in the nucleus shape and structure of fragmentation is the most important indicator of cellular damage. The morphological changes include chromatin condensation, formation of apoptotic cells, aneuploid DNA and DNA fragmentation. In some of the previous studies carried out on animals and in vitro conditions investigating the toxic effects of chromium compounds, some Cr+3 complexes have caused genotoxic and cytotoxic damages [27], whereas no adverse effects has been reported in the others [35].

Stearns et al. [30] suggested that both soluble and particular forms of CrPic ranging from 50 μM to 1.0 mM doses and picolinic acid doses higher than 40 μg/cm2 were clastogenic in Chinese hamster ovary. These authors showed that relatively high doses generated clastogenic effects, and cell cycling was retarded and metaphase was reduced due to the toxic effects of the high chromium levels. Komorowski et al. [33], investigated cytogenetic the effects of CrPic on bone marrow of Sprague-Dawley rats receiving diet supplemented with 33, 250 or 2000 mg/kg CrPic and showed no chromosomal abnormalities in male or female rats. High levels of dietary CrPic given to rats (2500 mg/kg) and mice (50,000 mg/kg) caused neither chromosomal aberrations nor increases in micronuclei frequency [50].

In a study by Whittaker et al. [36] who evaluated the cellular toxicity and mutagenicity of CrPic, CrCl3 and picolinic acid in Salmonella typhimurium and in L5178Y mouse lymphoma mutation assay, no mutagenic effects due to CrPic and CrCl3 in the bacteria were reported. However, these authors showed mutagenic response induced by relatively nontoxic doses of these chromium compounds in the L5178Y mouse. İmamoğlu et al. [29] also reported the increases in the frequency of MN in lymphocytes of calves receiving 400 μg CrPic daily but they determined no increase in calves receiving 200 μg CrPic. However, in the present study, the frequencies of MN and NBUD in chromium (III) chloride, CrPic and its moiety picolinic acid receiving rabbits was in the reduction trend. CrPic and picolinic acid reduced NPK frequency. The more pronounced declines were determined with CrPic and picolinic acid (p=0.007) considering the MN frequency whereas the decrease in NBUD (p=0.001) and NPK (p=0.000) were significant solely in picolinic acid receiving animals.

Manygoats et al. [27] reported CrPic-induced morphological changes in CHO AA8 cells. They found increases in apoptosis with the increasing CrPic levels which was consistent with the results of the study performed by İmamoğlu et al. [29] indicating a dose-dependent increase of the percentage of irregularly shaped and fragmented nuclei and apoptotic cells. Shirivastava et al. [28] have claimed that the 1, 10, 50 ve 100 μM doses of trivalent chromium complexes such as CrPic, CrCl3, [Cr(salen)(H2O)2]+, [Cr(EDTA)(H2O)]−, [Cr(en)3]3+,and [Cr(ox)3]3− were cytotoxic at nuclear level in human dermal fibrocyst. On the other hand, in the present study, no difference was observed in apoptotic cell percentage on 25th day of treatment whereas the percentages of necrotic cell were reduced (p=0.000) by CrCl3·6H2O, CrPic and picolinic acid but the decrease was significant (p=0.000) only in picolinic acid receiving rabbits on 50th day of treatment. Lack of the influence of CrCl3·6H2O and CrPic on apoptotic cell generation whereas causing reduction in necrotic cell formation confirms the findings of Komorowski et al. [33] who evaluated the cytogenetic effects of CrPic in bone marrow cells of Sprague-Dawley rats dosed orally with 33, 250 or 2000 mg/kg of CrPic and found no chromosomal anomalies.

Determination of inconsistent results with some previous studies indicating that chromium complexes produce genotoxic and cytotoxic effects may be due to the use of lower chromium doses than those studies [29], [30], [32], [36].

The results of this study have showed that supplementation of 20 mg/kg CrCl3·6H2O, 200 μg CrPic and 1400 μg picolinic acid for a short-term provided improvements in MDA and 8-OHdG levels instead of genotoxic and cytotoxic effects. CrPic can be used for reducing oxidative and chromosomal DNA damage.

Acknowledgements

This study was supported by the Scientific Research Projects Commission of Erciyes University, project number: TSD-10-3326, and summarized from PhD thesis., (Grant / Award Number: ‘16.409 Türkish Liras’).

  1. Conflict of interest: There are no conflicts of interest among the authors.

References

1. Mossop RT. Effects of chromium (III) on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetic. Central African J Med 1983;29:80–2.Search in Google Scholar

2. Striffler JS, Law JS, Polansky MM, Bhathena SJ, Anderson RA. Chromium improves insulin response to glucose in rats. Metabolism 1995;44:1314–20.10.1016/0026-0495(95)90036-5Search in Google Scholar

3. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. Am Coll Nutr 2001;20:212–8.10.1080/07315724.2001.10719034Search in Google Scholar PubMed

4. Ducros V. Chromium metabolism. A literature review. Biol Trace Elem Res 1992;32:65–77.10.1007/BF02784589Search in Google Scholar PubMed

5. Chen SY, Lien TF. Toxicity evaluation of chromium picolinate nanoparticles in vivo and in vitro in rat. Biol Trace Elem Res 2013;151:247–55.10.1007/s12011-012-9545-zSearch in Google Scholar PubMed

6. Prasad AS. Chromium. Trace elements and iron in human metabolism. New York: John Wiley & Sons LTD, 1978:3–12.10.1007/978-1-4684-0793-8_1Search in Google Scholar

7. World Health Organisation. Chromium. Genova, 1996:155–9.10.18356/9789213586273c157Search in Google Scholar

8. Sell JL. The role of chromium in animal nutrition. Washington: National Academy Press, 1997:80.Search in Google Scholar

9. Lukaski HC, Siders WA, Penland JG. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutr 2007;23:187–95.10.1016/j.nut.2006.12.001Search in Google Scholar PubMed

10. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab 1999;1:331–7.10.1046/j.1463-1326.1999.00055.xSearch in Google Scholar PubMed

11. İnanç N, Uyanık F, Şahin H, Yaman H, Erdem O. Effects of chromium supplementation on body composition, leptin, ghrelin levels and selected biochemical parameters in obese women. Trace Elem Electrol 2006;23:128–33.10.5414/TEP23128Search in Google Scholar

12. Cupo MA, Donaldson WE. Chromium and vanadium effects on glucose metabolism and lipid synthesis in the chick. Poultry Sci 1987;66:120–6.10.3382/ps.0660120Search in Google Scholar PubMed

13. Lien TF, Horng YM, Yang KH. Performance, serumcharactesictics, carcase traits and lipid metabolism of broilers as affected by supplement of chromium picolinate. Br Poult Sci 1999;40: 357–63.10.1080/00071669987458Search in Google Scholar PubMed

14. Uyanık F, Atasever A, Özdamar S, Aydın F. Effects of dietary chromium chloride supplementation on performance, some serum parameters and immune response in broilers. Biol Trace Elem Res 2002;90:99–115.10.1385/BTER:90:1-3:99Search in Google Scholar

15. Eren M, Başpınar N. Effects of dietary CrCl3 supplementation on some serum biochemical markers in broilers, Influence of season, age and sex. Revue de Med Vet 2004;155:637–41.Search in Google Scholar

16. Smith KL, Waldron MR, Drackley JK, Socha MT, Overton TR. Performance of dairy cows as affected by prepartum dietary carbohydrate source and supplementation with chromium throughout the transition period. J Dairy Sci 2005;88:255–63.10.3168/jds.S0022-0302(05)72683-7Search in Google Scholar

17. Şentürk (Gültekin) M, Uyanık F. Yumurtacı bıldırcınlarda oluşturulan ısı stresinde krom ve çinkonun bazı kan parametrelerine etkileri. J Fac Vet Med Univ Erciyes 2016;13:38–49.Search in Google Scholar

18. Uyanık F. The effects of dietary chromium supplementation on some blood parameters in sheep. Biol Trace Elem Res 2001;84:93–101.10.1385/BTER:84:1-3:093Search in Google Scholar

19. Uyanık F, Eren M, Kocaoğlu Güçlü B, Şahin N. Effects of dietary chromium supplementation on performance, carcass traits, serum metabolites, and tissue chromium levels of Japanese quails. Biol Trace Elem Res 2005;103:187–97.10.1385/BTER:103:2:187Search in Google Scholar

20. Uyanık F, Kocaoğlu Güçlü B, Can Şahna K, Dagalp SB, Erdem O. Effects of chromium picolinate on weight gain, selected blood metabolites, leptin and immunity in calves. J Anim Vet Adv 2008;7:564–9.Search in Google Scholar

21. Vincent JB. The potential value and toxicity of chromium picolinate as a nutritional supplement, weight loss agent and muscle development agent. Sports Med 2003;33:213–30.10.2165/00007256-200333030-00004Search in Google Scholar

22. Vinson JA, Mandarano MA, Shuta DL, Bagchi M, Bagchi D. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract and a niacin-bound chromium in a hamster atherosclerosis model. Mol Cell Biochem 2002;240:99–103.10.1023/A:1020611925819Search in Google Scholar

23. Mozaffari MS, Abdelsayed R, Liu JY, Wimborne H, El-Remessy A, El-Marakby A. Effects of chromium picolinate on glycemic control and kidney of the obese Zucker rat. Nutr Met 2009;6:51.10.1186/1743-7075-6-51Search in Google Scholar

24. Mozaffari MS, Baban B, Abdelsayed R, Liu JY, Wimborne H, Rodriguez N, et al. Renal and glycemic effects of high-dose chromium picolinate in db/db mice: assessment of DNA damage. J Nutr Biochem 2012;23:977–85.10.1016/j.jnutbio.2011.05.004Search in Google Scholar

25. Lukaski HC. Chromium as a supplement. Annu Rev Nutr 1999;19:289–302.10.1146/annurev.nutr.19.1.279Search in Google Scholar

26. Vincent JB. The bioinorganic chemistry of chromium (III). Polyhedron 2001;20:1–26.10.1016/S0277-5387(00)00624-0Search in Google Scholar

27. Manygoats KR, Yazzie M, Stearns DM. Ultrastructural damage in chromium picolinate-treated cells: a TEM study. J Biol Inorg Chem 2002;7:791–8.10.1007/s00775-002-0357-zSearch in Google Scholar

28. Shirivastava HY, Ravikumar T, Shanmugasundaram N, Babu M, Unni Nair B. Cytotoxicity studies of chromium (III) complexes on human dermal fibroblast. Free Radic Biol Med 2005;38:58–69.10.1016/j.freeradbiomed.2004.09.029Search in Google Scholar

29. İmamoğlu N, Uyanık F, Kocaoğlu Güçlü B, Erdem O, Liman BC, Dönmez Altuntaş H. Effects of chromium picolinate in micronucleus frequency and morphology of lymphocytes in calves. Biol Trace Elem Res 2008;125:133–40.10.1007/s12011-008-8163-2Search in Google Scholar

30. Stearns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produce chromosome damage in Chinese hamster ovary cells. FASEB J 1995;9:1643–8.10.1096/fasebj.9.15.8529845Search in Google Scholar

31. Bagchi D, Stohs SJ, Downs BW, Bagchi M, Preuss HG. Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicol 2003;180:175–7.10.1016/S0300-483X(02)00708-4Search in Google Scholar

32. Bailey MM, Boohaker JG, Sawyer RD, Behling JE, Rasco JF, Jernigan JJ, et al. Exposure of pregnant mice to chromium picolinate results in skeletal defects in their offspring. Birth Defects Res B Dev Reprod Toxicol 2006;77:244–9.10.1002/bdrb.20081Search in Google Scholar

33. Komorowski JR, Greenberg D, Juturu V. Chromium picolinate does not produce chromosome damage. Toxicol In Vitro 2008;22:819–26.10.1016/j.tiv.2007.12.007Search in Google Scholar

34. Hepburn DD, Vincent JB. Tissue and subcellular distribution of chromium picolinate with time after entering the bloodstream. J Inorg Biochem 2003;94:86–93.10.1016/S0162-0134(02)00623-2Search in Google Scholar

35. Rhodes MC, Hebert CD, Herbert RA, Morinello EJ, Roycroft JH, Travlos GS, et al. Absence of toxic effects in F344/N rats and B6C3F1 mice following subchronic administration of chromium picolinate monohydrate. Food Chem Toxicol 2005;43:21–9.10.1016/j.fct.2004.08.006Search in Google Scholar PubMed

36. Whittaker P, San RH, Clarke JJ, Seifried HE, Dunkel VC. Mutagenicity of chromium picolinate and its components in Salmonella typhimurium and L5178Y mouse Lymphoma cells. Food Chem Toxicol 2005;43:1619–25.10.1016/j.fct.2005.05.003Search in Google Scholar PubMed

37. Horwitz W, Chichilo P, Reynolds H, editors. Official methods of analysis 14th ed. USA: Association of analytical chemists, AOAC International; 1984.Search in Google Scholar

38. Carpenter KJ, Clegg KM. The metabolizable energy of poultry feeding stuffs in relation to their chemical composition. J Sci Feed Agric 1956;7:45–51.10.1002/jsfa.2740070109Search in Google Scholar

39. Chen KL, Lu JJ, Lien TF, Chiou PW. Effects of chromium nicotinate on performance, carcase characteristics and blood chemistry of growing turkeys. Br Poult Sci 2001;42:399–404.10.1080/00071660120055403Search in Google Scholar PubMed

40. Stout MD, Nyska A, Collins BJ, Witt KL, Kissling GE, Malarkey DE, et al. Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years. Food Chem Toxic 2009;47:729–33.10.1016/j.fct.2009.01.006Search in Google Scholar PubMed PubMed Central

41. Golubnitschaja O, Yeghiazaryan K. Opinion controversy to chromium picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case reports or recognising individual risks and new guidelines urgency to introduce innovation by predictive diagnostics? EPMA J 2012;3:3–11.10.1186/1878-5085-3-11Search in Google Scholar PubMed PubMed Central

42. Feng Z, Hu W, Marnett LJ, Tang MS. Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV and BPDE induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat Res 2006;601:125–36.10.1016/j.mrfmmm.2006.06.003Search in Google Scholar PubMed

43. Fujii J, Iuchi Y, Okada F. Fundamental roles of reactive oxygen species and protective mechanisms in the female reproductive system. Reproduce Biol Endocrinol 2005;3:43.10.1186/1477-7827-3-43Search in Google Scholar PubMed PubMed Central

44. Preuss HG, Grojec PL, Lieberman S, Anderson RA. Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneusly hypertensive rats. Clin Nephrol 1997;47:325–30.Search in Google Scholar

45. Anderson RA, Polansky MM. Dietary and metabolite effects on trivalent chromium retention and distribution in rats. Biol Trace Elem Res 1995;50:97–108.10.1007/BF02789412Search in Google Scholar PubMed

46. Dinçer Y, Erzin Y, Himmetoğlu S, Gunes KN, Bal K, Akcay T. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci 2007;52:1636–41.10.1007/s10620-006-9386-8Search in Google Scholar PubMed

47. Tsou TC, Chen CL, Liu TY, Yang JL. Induction of 8-hydroxy deoxyguanosine in DNA by chromium (III) plus hydrogen peroxide and its prevention by scavengers. Carsinogenesis 1996;17:103–8.10.1093/carcin/17.1.103Search in Google Scholar PubMed

48. Chang WC, Yu YM, Wu CH, Tseng YH, Wu KY. Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. Can J Physiol Pharmacol 2005;83: 423–30.10.1139/y05-028Search in Google Scholar PubMed

49. Hamurcu Z, Bayram F, Kahrıman G, Dönmez-Altuntas H, Baskol G. Micronucleus frequency in lymphocytes and 8-hydroxydeoxyguanosine level in plasma of women with polycystic ovary syndrome. Gynecol Endocrinol 2010;26:590–5.10.3109/09513591003632142Search in Google Scholar PubMed

50. Committee on mutagenicity of chemicals in food. Statement on the mutagenicity of trivalent Cr and CrPic. Consumer Products and Environment COM/04/S3. Available at: http://www.advisorybodies.doh.gov.uk/Com/chromium.htm. Accessed: Dec 2013.Search in Google Scholar

Received: 2016-11-01
Accepted: 2017-08-10
Published Online: 2017-09-09
Published in Print: 2018-03-01

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Research Articles
  3. A Src/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents
  4. Effects of chromium picolinate on the parameters of oxidative and chromosomal DNA damage in rabbits
  5. Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
  6. Evaluation of apoptotic caspase levels in estimation of the wound age
  7. Use of immunohistochemical versus microsatellite analyses as markers for colorectal cancer
  8. Estimation of the Y-chromosomal short tandem repeat (Y-STR) mutation rates in Turkey
  9. Synthesis and evaluation of new benzimidazole derivatives with hydrazone moiety as anticancer agents
  10. Effects of chemoradiotherapy on acute-phase protein levels in glioblastoma multiforme and locally advanced non-small cell lung cancer
  11. Association between polymorphisms of DNA repair genes and risk of type 2 diabetes mellitus in the Turkish population
  12. Letter to the Editor
  13. Association of CTLA-4 polymorphisms and autoimmune type-1 diabetes mellitus susceptibility in Pakistani population
  14. Research Articles
  15. The effects of royal jelly on the oxidant-antioxidant system in rats with N-methyl-N-nitrosourea-induced breast cancer
  16. Meta-analysis of the relationship between MnSOD polymorphism and cancer in the Turkish and Cypriot population
  17. Resveratrol induces cell cycle arrest and apoptosis in epithelioid malignant pleural mesothelioma cells
https://doi.org/10.1515/tjb-2016-0220
Keywords for this article
Apoptosis; Chromium picolinate; DNA damage; Micronucleus; Oxidative stress

Articles in the same Issue

  1. Frontmatter
  2. Research Articles
  3. A Src/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents
  4. Effects of chromium picolinate on the parameters of oxidative and chromosomal DNA damage in rabbits
  5. Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
  6. Evaluation of apoptotic caspase levels in estimation of the wound age
  7. Use of immunohistochemical versus microsatellite analyses as markers for colorectal cancer
  8. Estimation of the Y-chromosomal short tandem repeat (Y-STR) mutation rates in Turkey
  9. Synthesis and evaluation of new benzimidazole derivatives with hydrazone moiety as anticancer agents
  10. Effects of chemoradiotherapy on acute-phase protein levels in glioblastoma multiforme and locally advanced non-small cell lung cancer
  11. Association between polymorphisms of DNA repair genes and risk of type 2 diabetes mellitus in the Turkish population
  12. Letter to the Editor
  13. Association of CTLA-4 polymorphisms and autoimmune type-1 diabetes mellitus susceptibility in Pakistani population
  14. Research Articles
  15. The effects of royal jelly on the oxidant-antioxidant system in rats with N-methyl-N-nitrosourea-induced breast cancer
  16. Meta-analysis of the relationship between MnSOD polymorphism and cancer in the Turkish and Cypriot population
  17. Resveratrol induces cell cycle arrest and apoptosis in epithelioid malignant pleural mesothelioma cells
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 20.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/tjb-2016-0220/html?lang=en
Scroll to top button